Revenue from Contracts with Customers.

In accordance with Accounting Standards Update ("ASU") 2014-09, Revenue from Contracts with Customers (Topic 606) ("ASC 606"), we recognize revenue when a customer obtains control of promised goods. The amount of revenue recognized reflects the consideration we to receive in exchange for these goods. To achieve this core principle, we apply the following five steps:

Identify the contract with the customer. A contract with a customer exists when (i) we enter into an enforceable contract with a customer that defines each party’s rights regarding the goods to be transferred and identifies the payment terms related to these goods, (ii) the contract has commercial substance and, (iii) we determine that collection of substantially all consideration for services that are transferred is probable based on the customer’s intent and ability to pay the promised consideration. We do not have significant costs to obtain contracts with customers. For commissions on product sales, we have elected the practical expedient to expense the costs as incurred if the amortization period would have been one year or less.

Identify the performance obligations in the contract. Generally, our contracts with customers do not include multiple performance obligations to be completed over a period of time. Our performance obligations relate to delivering single-use medical products to a customer, subject to the shipping terms of the contract. Limited warranties are provided, under which we typically accept returns and provide either replacement parts or refunds. We do not have significant returns. We do not typically offer extended warranty or service plans.

Determine the transaction price. Payment by the customer is due under customary fixed payment terms, and we evaluate if collectability is reasonably assured. None of our contracts as of June 30, 2018 contained a significant financing component. Further, our methodology to estimate and recognize variable consideration is consistent with the requirements of ASC 606. Revenue is recorded at the net sales price, which includes estimates of variable consideration such as product returns, rebates, discounts, and other adjustments. The estimates of variable consideration are based on historical payment experience, historical and projected sales data, and current contract terms. Variable consideration is included in revenue only to the extent that it is probable that a significant reversal of the revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Taxes collected from customers relating to product sales and remitted to governmental authorities are excluded from revenues.


4.	Allocate the transaction price to performance obligations in the contract. We typically do not have multiple performance obligations in our contracts with customers. As such, we recognize revenue upon delivery of the product to the customer's control at contractually stated pricing.


5.	Recognize revenue when or as we satisfy a performance obligation. We satisfy performance obligations at a point in time upon either shipment or delivery of goods, in accordance with the terms of each contract with the customer. We do not have significant service revenue.

Disaggregation of Revenue

The disaggregation of revenue is based on type of product and geographical region. For descriptions of our product offerings and segments, see Note 12 in our 2017 Form 10-K.

The following tables present revenue from contracts with customers for the three and six-month periods ended June 30, 2018 and 2017 (in thousands):



	Three Months Ended June 30, 2018						Three Months Ended June 30, 2017
	United States		International		Total		United States		International		Total
Cardiovascular
Stand-alone devices	$	50,941	$	41,555	$	92,496	$	37,202	$	33,854	$	71,056
Custom kits and procedure trays	23,667		10,325		33,992		24,271		7,526		31,797
Inflation devices	8,160		16,145		24,305		8,042		12,747		20,789
Catheters	16,704		22,670		39,374		16,022		16,407		32,429
Embolization devices	5,094		7,630		12,724		5,593		6,565		12,158
CRM/EP	11,758		1,738		13,496		10,264		1,170		11,434
Total	116,324		100,063		216,387		101,394		78,269		179,663

Endoscopy
Endoscopy devices	8,121		302		8,423		6,712		174		6,886

Total	$	124,445	$	100,365	$	224,810	$	108,106	$	78,443	$	186,549



	Six Months Ended June 30, 2018						Six Months Ended June 30, 2017
	United States		International		Total		United States		International		Total
Cardiovascular
Stand-alone devices	$	94,953	$	80,789	$	175,742	$	73,366	$	61,343	$	134,709
Custom kits and procedure trays	45,984		21,280		67,264		45,737		14,935		60,672
Inflation devices	15,828		30,896		46,724		16,017		23,279		39,296
Catheters	31,974		41,265		73,239		31,151		31,454		62,605
Embolization devices	10,126		15,184		25,310		11,134		13,551		24,685
CRM/EP	20,596		3,366		23,962		20,011		2,440		22,451
Total	219,461		192,780		412,241		197,416		147,002		344,418

Endoscopy
Endoscopy devices	15,040		563		15,603		12,806		394		13,200

Total	$	234,501	$	193,343	$	427,844	$	210,222	$	147,396	$	357,618